Cheung Laboratories
This article was originally published in The Gray Sheet
Executive Summary
Microwave technology manufacturer changes its name to Celsion to reflect the company's underlying purpose - to use focused heat technology to kill cancer cells. The firm recently filed an investigational device exemption with FDA to begin clinical studies of its microwave benign prostatic hyperplasia treatment system, which incorporates a microwave balloon catheter for transurethral microwave heating to shrink the prostate and compress the urethra wall. "The combination of microwave heat and balloon catheter compression creates a natural biological stent in the urethra, providing immediate relief of urinary obstruction," the company explains in an April 27 release
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.